National Comprehensive Cancer Network appoints board of directors chair, vice chair
Click Here to Manage Email Alerts
Matt Kalaycio, MD, FACP, has been elected chair of National Comprehensive Cancer Network’s board of directors.
Christopher H. Lieu, MD, has been elected vice chair.
“The exemplary leadership from our board of directors is invaluable as NCCN defines and advances high-quality, high-value, patient-centered cancer care around the world,” Crystal S. Denlinger, MD, CEO of NCCN, said in a press release. “Their steady guidance during a transitional time helps us maintain our highly trusted, continuously updated, evidence-based, expert consensus recommendations for cancer care, which were accessed more than 15 million times in 2023 alone. I look forward to working even more closely with Matt and Chris and relying on the substantial expertise, caring, and leadership they bring to these positions.”
Kalaycio is vice chair of Cleveland Clinic Cancer Institute and professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He specializes in the treatment of leukemia, hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy.
"NCCN is committed to ensuring that all [people with cancer] receive the latest evidence-based treatment options by not only informing health care providers of available treatments, but also offering education and support to the patients and their caregivers,” said Kalaycio, who had served as the board’s vice chair since 2022. “As I take on the role of chair of the NCCN board of directors, I eagerly anticipate further advancing the organization’s mission."
Kalaycio succeeds previous board chair John W. Sweetenham, MD, FRCP, FACP, FASCO, associate director for clinical affairs at Harold C. Simmons Comprehensive Cancer Center and Healio | HemOnc Today Chief Medical Editor Emeritus.
“We are grateful for everything John has done over the years to improve the lives of people with cancer, both through his work with NCCN and throughout his illustrious career,” Denlinger said. “He has been a beacon of stable, supportive governance. We will always appreciate the time and thoughtfulness he has shared with us.”
Lieu is associate professor, co-director of gastrointestinal medical oncology and associate director for clinical research at University of Colorado Cancer Center. He specializes in gastrointestinal cancer, and his research focus includes novel strategies to treat and prevent colorectal cancer among young adults.
“I am very honored to serve as the vice-chair of the NCCN Board of Directors,” Lieu said. “I am thrilled to take on this role and am also looking forward to continuing to learn from, and interact with, the incredible leadership at NCCN.”
Click Here to Manage Email Alerts